Harnessing PCORnet to Study Comparative Effectiveness and Safety of Biologic Therapies

Harnessing PCORnet to Study Comparative Effectiveness and Safety of Biologic Therapies

Lead Principal Investigator: Jeffrey R. Curtis, MD, MPH, MS

Organization: University of Alabama at Birmingham

Purpose: To improve decision-making when choosing treatments for autoimmune and inflammatory diseases by looking at the relationship between newer biologic agents being used to treat these diseases and important safety events of hospitalized infection, heart attack, stroke, and cancer.

Funded through a Patient-Centered Outcomes Research Institute (PCORI) Award (PPRND-1507-32163).

Harnessing PCORnet to Study Comparative Effectiveness and Safety of Biologic Therapies

Lead Principal Investigator: Jeffrey R. Curtis, MD, MPH, MS

Organization: University of Alabama at Birmingham

Purpose: To improve decision-making when choosing treatments for autoimmune and inflammatory diseases by looking at the relationship between newer biologic agents being used to treat these diseases and important safety events of hospitalized infection, heart attack, stroke, and cancer.

Funded through a Patient-Centered Outcomes Research Institute (PCORI) Award (PPRND-1507-32163).

Overview

The study is in development

who's involved?

sites

7 participating Networks:
AR-PoWER, PARTNERS, CCFA Partners, ImproveCareNow, Vasculitis, Mid-South CDRN, PEDSnet

how we're making a difference

Investigators use clinical data network resources to identify persons with the autoimmune and inflammatory conditions of interest and invite them to join the respective people-powered networks, providing these groups with new, previously unidentified members.
Throughout this process, researchers engage patients and other stakeholders from partner networks in the design of the studies, including the creation of a steering committee with patient representation.
Investigators will disseminate study findings broadly throughout associated professional societies and national patient advocacy groups.